Experience

• • Clayton, Dubilier & Rice in the financing aspects of its investment in Columbus McKinnon to fund Columbus McKinnon’s $2.7 billion acquisition of Kito Crosby.
  • Elliott in the financing aspects of the sale of its majority-owned interest in Roadrunner Transportation to Prospero Staff Capital.
  • Clayton, Dubilier & Rice in the financing aspects of its acquisition, together with TowerBrook Capital Partners, of R1 RCM.
  • Focus Financial Partners in the $4.276 billion refinancing of Focus’s existing debt facilities.
  • Wilsonart, a Clayton, Dubilier & Rice portfolio company and engineered surfaces company, in its $1.8 billion refinancing consisting of a $1.1 billion Senior Secured Term Loan Facility, $500 million senior notes offering and $250 million Senior Secured Revolving Facility.
  • Cornerstone Building Brands, a manufacturer of exterior building products, in its offering of $500 million senior secured notes due 2029.
  • Cornerstone Building Brands in the financing aspects of its acquisition of Harvey, a manufacturer of high performing windows and doors.
  • Artera Services and Clayton, Dubilier & Rice in the $2 billion comprehensive refinancing for Artera.
  • Prudential Financial in the financing aspects of the formation of Prismic Life Reinsurance, a licensed Class E Bermuda-based life and annuity reinsurance company.
  • TPG Growth in the financing aspects of its acquisition of a majority stake in Crowe Healthcare Consulting, establishing it as an independent entity.
  • Elliott in the financing aspects of its investment leading Speyside’s single asset continuation fund to support the future growth of its portfolio company Opta.
  • Clayton, Dubilier & Rice in the financing aspects of its $2.3 billion acquisition of Veritiv Corporation, a full-service provider of packaging.
  • Clayton, Dubilier & Rice in the financing aspects of its $5.8 billion acquisition of Cornerstone Buildings Brands, the largest manufacturer of exterior buildings products in North America.
  • Carlyle in the financing aspects of its strategic partnership with Orsini, an independent specialty pharmacy focused on rare diseases, gene therapies and complex conditions.